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ABSTRACT: A number of amphiphilic difatty acyl linear and
cyclic R5K2 peptide conjugates were synthesized by solid-phase
peptide methods to enhance the interaction with the
hydrophobic cellular phospholipid bilayer and to improve
siRNA delivery and silencing. Binding to siRNA molecules was
signiﬁcantly less for the cyclic peptide conjugates. A gradual
decrease was observed in the particle size of the complexes
with increasing peptide/siRNA ratio for most of the
synthesized peptides, suggesting the complex formation.
Most of the complexes showed a particle size of less than
200 nm, which is considered an appropriate size for in vitro
siRNA delivery. A number of fatty acyl-conjugated peptides, such as LP-C16 and LP-C18, displayed near complete protection
against serum degradation. Flow cytometry studies demonstrated signiﬁcantly higher internalization of ﬂuorescence-labeled
siRNA (FAM-siRNA) in the presence of LP-C16, LP-C18, and CP-C16 with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE) addition. Confocal microscopy conﬁrmed the cellular internalization of ﬂuorescence-labeled siRNA in the presence of
LP-C16 and LP-C18 with DOPE when compared with cells exposed to DOPE/FAM-siRNA. While C16- and C18-conjugated
peptides (especially linear peptides) showed silencing against kinesin spindle protein (KSP) and janus kinase 2 (JAK2) proteins,
the addition of DOPE enhanced the silencing eﬃciency signiﬁcantly for all selected peptides, except for CP-C16. In conclusion,
C16 and C18 difatty acyl peptide conjugates were found to enhance siRNA delivery and generate silencing of targeted proteins in
the presence of DOPE. This study provides insights for the design and potential application of optimized difatty acyl peptide/
lipid nanoparticles for eﬀective siRNA delivery.
■ INTRODUCTION
RNA interference (RNAi) is an alternative approach to
traditional medicine, which usually uses small molecules to
target speciﬁc molecules and/or aims to control symptoms of a
disorder. RNAi research has attracted signiﬁcant interest since
the dawn of the century. This approach is based on post-
transcriptional interference with the expression of a speciﬁc
protein (or in some cases, a family of proteins) that could be
involved in the pathology of the disorder. The possibility of this
“silencing” mechanism was reported in late 1990s by Fire et al.
who reported interference with the protein expression at the
mRNA level by delivering an exogenous double-stranded
RNA.1 Among diﬀerent approaches to RNAi, small-interfering
RNA (siRNA) is the closest to the small-molecule approach
because it does not alter the genetic information of the cell,
does not require incorporation into the chromosome, and
creates a dose-dependent and transient eﬀect.
Although siRNA silencing is temporary and the eﬀect is
limited to the number of RNA strands delivered to the cell, the
siRNA approach to RNAi oﬀers several advantages, which
include the following: (i) unlike short hairpin RNAs and micro-
RNAs, siRNA is ready to use and does not require intracellular
processing; (ii) it is only needed in the cytoplasm and not in
the nucleus, which eliminates the need for intranuclear delivery;
(iii) it is highly speciﬁc, which is speciﬁcally advantageous in
basic research, by eliminating oﬀ-target eﬀect and enabling
researchers to evaluate the functionality of the targeted protein;
and (iv) as mentioned before, among diﬀerent RNAi
approaches, siRNA is the closest to a traditional “drug”,
which is feasible in vivo and can be applicable to clinical
settings. Despite these advantages, however, the use of siRNA
in clinical settings has been marred by a few challenges for
eﬃcient siRNA delivery. Whereas in vivo delivery of siRNA is
shown to be a daunting task, even in vitro siRNA delivery has
been challenging and inconsistent because of the hydrophilic
nature of the siRNA molecule (which minimizes its interaction
with the cell membrane) and its negative electronic charge (due
to the presence of phosphate groups on the backbone of the
nucleotides, which is repulsed by the negatively charged cell
membrane).2 In vitro siRNA delivery has been studied
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extensively for a variety of purposes, including evaluating the
eﬃciency of a novel delivery system, investigating the
intracellular functions of a speciﬁc protein, and determining
the potential therapeutic eﬀect of silencing speciﬁc proteins.
Many diﬀerent categories of carriers have been studied for
siRNA delivery, which include polymers, lipids, and peptides.
Short sequences of amino acids (less than 30) have been
studied as delivery systems since the late 20th century.
Speciﬁcally, cell-penetrating peptides (CPPs) are 5−40 amino
acid-long peptides that are known for their ability to internalize
their cargo into the cell and have been used for siRNA delivery
as well.3,4 The exact mechanism of cellular uptake has been a
subject of debate; however, macropinocytosis, signal-activated
endocytosis, and “inverted micelle” model have been
suggested.5 Positively charged amino acids, for example,
arginine and lysine, are required for complex formation with
siRNA,6 and it has been suggested that intracellular delivery
could be optimized by adjusting the number of arginines in the
peptide.7 Recent reports indicate the in vitro use of folate-
poly(ethylene glycol) PEG-appended dendrimer/α-cyclodex-
drin conjugates for delivering siRNA to keratin-forming tumor
cell line, HeLa (KB) cells (ATCC CCL-17),8 polyelectrolyte-
gold nanoassemblies to deliver β-site APP cleaving enzyme1
siRNA to murine neuronal cell lines,9 polycation liposome-
encapsulated calcium phosphate nanoparticles for vascular
endothelial growth factor (VEGF) siRNA delivery to the MCF-
7 breast cancer cell line,10 and folic acid-modiﬁed mesoporous
silica nanocarriers to deliver VEGF siRNA to HeLa cells over-
expressing folic acid.11 The most recent developments in
siRNA delivery include stable nucleic acid lipid particles
(SNALPs) and N-acetylgalactosamine (GalNAc). SNALPs are
multicomponent liposome-like particles that use neutral and
cationic lipids for a more eﬀective siRNA delivery12,13 and has
reached clinical trials for a few formulations.14 GalNAc, on the
other hand, is a liver-targeting moiety with high aﬃnity for
asialoglycoprotein receptor, which has been studied as a direct
conjugation to siRNA or a component in the delivery
system.15,16
We have reported the application of cyclic CPPs containing
arginine (R) and tryptophan (W) residues or fatty acyl chains
for delivery of diﬀerent cargo molecules including negatively
charged phosphopeptides.17,18 Cyclic peptides are more rigid
and expected to be more stable toward degradation. The cyclic
nature of the peptides provides higher stability versus the linear
counterparts and a more eﬃcient cell penetration. Recently, we
also reported that [WR]5 and [WR]5-capped gold nanoparticles
improved the cellular delivery of siRNA in HeLa cells by 2- and
3.8-fold, respectively.19
Our earlier work also showed that short linear peptide
amphiphiles containing arginine and lysine that conjugated with
two fatty acyl groups of hexadecanoyl groups were able to act as
a molecular transporter of negatively charged phosphopeptide
(PEpYLGLD) intracellularly.17 We have previously reported
monofatty acyl conjugates of cyclic peptides containing ﬁve and
six arginine residues.20 Two conjugates, dodecanoyl-[R5] and
dodecanoyl-[R6], improved the cellular uptake of a cell-
impermeable negatively charged phosphopeptide (GpYEEI)
by 3.4-fold and 5.5-fold, respectively, in human ovarian cancer
cells, suggesting that a combination of peptide cyclization and
fatty acylation can be used to improve the intracellular uptake
of compounds with limited cell permeability.
On the basis of the previous data on the importance of the
presence of fatty acyl chains and positively charged peptides for
cellular delivery eﬃciency, we report here the design, synthesis,
characterization, and evaluation of linear and cyclic peptides
conjugated with two fatty acyl chains for siRNA delivery. To
the best of our knowledge, no cyclic and linear peptides
containing two fatty acyl chains and ﬁve arginine residues have
been reported previously for siRNA delivery. We hypothesized
that the combination of two fatty acids and positively charged
peptides will enhance the interaction with the two hydrophobic
chains and negatively charged phosphate in the cellular
Figure 1. Chemical structures of difatty acyl linear and cyclic peptide conjugates.
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phospholipid bilayer, respectively, and enhance the cellular
delivery of siRNA and siRNA silencing. Two lipid tails of the
peptide are expected to increase the hydrophobic interior
interactions with the cellular membrane. One of the objectives
of this research was to determine whether the side chain length
of the fatty acyl conjugates and the linear or cyclic nature of the
peptides can aﬀect the cellular internalization. For this purpose,
a variety of linear and cyclic peptides were synthesized with
various fatty acyl conjugations with diﬀerent lengths (from C2
to C18) and degrees of saturation. Both linear and cyclic
peptides had the same amino acid sequence of R5K2 as the
backbone (Figure 1). (R5K2) and [R5K2] represent the number
and presence of ﬁve arginine and two lysine residues in linear
and cyclic peptides, respectively. The sequences are KRKR4 and
[KRKR4] for linear and cyclic peptides, respectively. For
simplicity, the backbone of both group of peptides is shown as
R5K2. For convenience, square brackets [ ] and parentheses ( )
were used to represent cyclic and linear peptides, respectively.
The diversity in hydrophobicity of the compounds allows
studying the interactions with siRNA and transfection
eﬃciency. We analyzed the amount of peptide required for
50% binding to siRNA (BC50, as an indirect method of
estimating “binding aﬃnity”) to determine the eﬀect of lipid
conjugation and the size of the conjugate on the interionic
interaction. The ability of the peptides in protecting siRNA
against early enzymatic degradation was investigated by
exposing the complexes to fetal bovine serum (FBS), and the
toxicity of the peptides was explored in diﬀerent human cancer
cell lines. We characterized the size and surface electrical charge
of the complexes formed via ionic interaction between the
peptides and siRNA to conﬁrm complex formation and
neutralization of siRNA negative charge and to evaluate the
physical characteristics of the complex. Finally, the eﬃciency of
Scheme 1. (A) Synthesis of Linear N-Free Amino Difatty Acyl Conjugates of R5K2; (B) Synthesis of Linear N-Acetylamino
Difatty Acyl Conjugates of R5K2
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the peptide libraries in internalizing siRNA into diﬀerent
human cancer cells was studied, which was conﬁrmed by the
silencing eﬃciency for a model protein.
■ RESULTS
Chemistry. Fmoc solid-phase peptide synthesis was used to
synthesize the cyclic and linear difatty acyl conjugates of the
designed peptides with ﬁve arginines and two lysines (R5K2)
(Schemes 1 and 2). Protected Arg(Pbf)-Wang resin was used as
a solid support for the linear peptide synthesis, and Fmoc-
Arg(Pbf)-OH and Fmoc-Lys(Dde)-OH or Boc-Lys(Fmoc)-
OH were used as building block amino acids. After
deprotection of the Fmoc group and activation of the amino
group, Dde groups of lysine residues were selectively
deprotected in the presence of hydrazine in dimethylformamide
(DMF, 2:98 v/v). Prior to the ﬁnal cleavage of the linear
peptide conjugates, the fatty acid conjugations were carried out
with the resin-attached linear peptide. Fatty acid conjugation
was performed in the presence of 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HBTU) and
N,N-diisopropylethylamine (DIPEA). The ﬁnal cleavage was
performed in the presence of triﬂuoroacetic acid (TFA)/
anisole/thioanisole/dithiothreitol (DTT) (94:2:2:2 v/v/v/v)
(Scheme 1).
2-Chlorotrityl arginine resin was used as a solid support for
the synthesis of difatty acyl cyclic peptide conjugates. Fmoc-
Arg(Pbf)-OH and Fmoc-Lys(Boc)-OH were used as the
building block amino acids. After assembly of the peptide on
the solid phase, the resin was cleaved in the presence of
dichloromethane (DCM)/triﬂuoroethanol/AcOH (1:2:7 v/v/
v). N- to C-cyclization was accomplished in the solution phase
and in the presence of 1-hydroxy-7-azabenzotriazole (HOAT)/
DIPEA. After deprotection of side chains in the presence of
TFA/anisole/thioanisole/DTT (94:2:2:2 v/v/v/v), fatty acid
conjugation was accomplished in the presence of HBTU and
DIPEA to aﬀord difatty acyl cyclic peptide conjugates (Scheme
2).
Fatty acids were (CH3(CH2)n−COOH) and dicarboxylic
acids were (HOOC(CH2)n−COOH), where n varied from 2 to
16. Also, linoleic acid was chosen as the fatty acid to
incorporate an analogue with an unsaturated bond in the
library. The structures of all conjugated linear and cyclic
peptides can be found in Figures S1 and S2 (Supporting
Information), respectively. The crude linear and cyclic difatty
acyl peptide conjugates were puriﬁed by reversed-phase high-
Scheme 2. Synthesis of Cyclic Difatty Acyl Conjugates of R5K2
Figure 2. BC50 of difatty acyl linear and cyclic peptides to siRNA. Representative line graph of siRNA binding of linear (A) and cyclic peptides (B)
to scrambled siRNA, indicating the percentage of siRNA bond to the peptide as a function of peptide/siRNA N/P ratios of 0−8 and 0−90
(compared to free siRNA as control), respectively.
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performance liquid chromatography (HPLC) and characterized
by matrix-assisted laser desorption ionization time-of-ﬂight
(MALDI-TOF). During the puriﬁcation process, it was
discovered that the polarity of the solvents aﬀected the
puriﬁcation process of the conjugates. For example, isopropanol
alcohol and methanol worked more eﬃciently when purifying
the hydrophobic C18 linear and cyclic conjugates.
BC50 for siRNA Binding. To evaluate the capability of
linear and cyclic peptides to form complexes with siRNA via
interionic interaction, a binding experiment was designed based
on the quantiﬁcation of bound siRNA using SYBR Green II,
and the data were used to calculate BC50 for each peptide.
Figure 2 summarizes the siRNA-binding of both libraries. The
ﬂuorescent signal quantiﬁed for the positive control was not
signiﬁcantly diﬀerent from the signal recorded for SYBR Green
added to siRNA-free saline (data not shown), which conﬁrmed
the reliability of the binding data. Among linear peptides, the
unmodiﬁed linear peptide (R5K2) showed the lowest BC50 for
binding to siRNA (BC50 = 0.7; n = 3). Hydrophobically
modiﬁed linear peptides showed two diﬀerent patterns for
siRNA binding; whereas most modiﬁed peptides showed a
strong siRNA-binding aﬃnity, LP-C2, LP-C4, LP-C6, and LP-
C10 did not follow this trend, and in fact, complete complex
formation was not observed even with the highest ratio studied
for these modiﬁed peptides. Among this group of peptides, LP-
C10 showed the lowest BC50 to form complexes with siRNA,
with almost no siRNA binding detected at any of the studied
peptide/siRNA ratios. The common theme among the fatty
acid-conjugated peptides with low aﬃnity for siRNA binding is
the terminal −COOH group at the end of the dicarboxylic fatty
acid used for conjugation. The only other modiﬁed peptide
with the −COOH group at the end of the conjugated fatty acid
was LP-C8, which showed ∼84% complex formation at an
nitrogen/phosphate (N/P) ratio of 7.0, with a relatively lower
BC50 (1.18) compared to other peptides (Figure 2A). The
ﬁnal ranking of the BC50 values calculated for peptides with
near-complete complex formation was LP (0.70) > LP-C12
(0.97) = LP-C18 (1.0) > LP-C8 (1.2) = LPC16 (1.2) > LP-
C14 (1.4) = LP-C18* (1.4) > LP-C8* (2.6).
Figure 3. Particle size and electrical surface charge of peptide/siRNA complexes. Hydrodynamic diameter of the linear (A) and cyclic (B) peptides/
siRNA complexes at diﬀerent w/w ratios. The particle size for most of the complexes at the peptide/siRNA w/w ratio of 20:1 (N/P ratios of 10.2−
29.5 for modiﬁed peptides) was about 200 nm or less. ζ-Potential of linear (C) and cyclic (D) peptides/siRNA complexes at diﬀerent w/w ratios.
Whereas most of the linear peptides showed a steady increase in the ζ-potential with a positive value for the 20:1 peptide/siRNA w/w ratio, many
cyclic peptides failed to show a similar trend, and a few reached a positive ζ-potential at the highest peptide/siRNA ratio studied in this experiment.
The error bars represent the standard deviation.
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The cyclic-modiﬁed peptides showed a more versatile proﬁle.
Only unmodiﬁed cyclic [R5K2] and four modiﬁed peptides
achieved complete complexation with siRNA at the highest N/
P ratio. The BC50 value of the unmodiﬁed cyclic peptide was
very similar to that of the linear counterpart (BC50 = 0.73);
however, modiﬁed cyclic peptides generally showed a higher
BC50. Whereas CP-C2, CP-C4, CP-C8, CP-C14, and CP-
C18* showed negligible aﬃnity to siRNA (less than 20%
complex formation at a w/w ratio of 80:1), CP-C6 and CP-C16
showed some aﬃnity and achieved ∼77 and ∼40% complex
formation at the highest studied peptide/siRNA ratio,
respectively (Figure 2B). The ﬁnal ranking of BC50 values
among the peptides that did show complete complexation was
CP (0.73) > CP-C10 (1.3) > CP-C12 (18) > CP-C8* (37) >
CP-C18 (38).
Size and Electrical Charge of Peptide/siRNA Com-
plexes. The in vitro and in vivo performances of siRNA
delivery systems largely depends on the size and overall surface
electrical charge of the siRNA-associated carrier. We used a
dynamic light scattering method to determine the size of the
peptide/siRNA complexes at four diﬀerent w/w ratios. For
most of the linear and cyclic peptides, a decline in the size of
the peptide/siRNA complexes was observed on increasing the
peptide/siRNA w/w ratio. This was speciﬁcally signiﬁcant for
LP-C2 (3171 vs 210 nm for ratios of 1:1 [N/P ratio of 1.12]
and 20:1 [N/P ratio of 22.4], respectively), LP-C8* (2590 vs
152 nm), CP-C14 (3349 vs 400 nm), CP-C16 (5020 vs 646
nm), and CP-C18 (2633 vs 168 nm). On the other hand, some
of the other peptides showed a rather steady size regardless of
the peptide/siRNA ratio (including LP, LPC4, LP-C6, CP-C2,
CP-C6, CP-C10, and CP-C12). Overall and at the highest ratio
studied in this experiment, most of the peptide/siRNA ratios
showed a hydrodynamic diameter of 200 nm or less. Among
these peptides, LP-C16 (57.47 nm), LP-C18 (92.78 nm), and
CP-C8 (103.12 nm) were the smallest complexes observed (all
sizes were measured in triplicates). However, some of the
peptide/siRNA complexes showed a hydrodynamic diameter
larger than 400 nm at this ratio, which included LP, CP-C12,
CP-C16, and CP-C18 (Figure 3A,B).
The ζ-potential of the nonmodiﬁed peptide/siRNA nano-
particles showed a steady increase on increasing the peptide/
siRNA w/w ratio (−0.83, 0.371, 2.4, and 3.3 for 1:1, 5:1, 10:1,
and 20:1 ratios equivalent to N/P ratios of 2.2, 11.0, 21.9, and
43.9, respectively). Most of the fatty acid-conjugated linear
peptides showed a similar pattern with a gradual increase in the
ζ-potential of the complexes. The only exception was LP-C4,
which after an initial increase (−0.701, 1.01, and 1.93 for
peptide/siRNA ratios of 1:1, 5:1, and 10:1 equivalent to N/P
ratios of 0.51, 2.55, and 5.1, respectively) demonstrated a
negative ζ-potential for the 20:1 peptide/siRNA w/w ratio (N/
P ratio of 10.2). LP-C14 was the only other modiﬁed peptide
that (despite a gradual increase in ζ-potential values)
demonstrated a negative value at the w/w ratio of 20:1
(equivalent to N/P ratio of 22.4; ζ-potential = −1.21). LP-C12,
LP-C16, LP-C18, and LP-C18* were the only peptides that
showed positive ζ-potential values for all studied peptide/
siRNA ratios and a signiﬁcant increase in the ζ-potential
compared to the unmodiﬁed linear peptide (Figure 3C). The
unmodiﬁed cyclic peptide also showed an increase in the ζ-
potential on increasing the peptide/siRNA ratio (−5.39, −3.7,
−1.9, and 0.101 for ratios of 1:1, 5:1, 10:1, and 20:1 equivalent
to N/P ratios of 2.23, 11.2, 22.3, and 44.6, respectively). A
similar pattern, however, was not observed for all of the
peptides in this library. CP-C12, CP-C16, and CP-C18
demonstrated negative ζ-potential values for all peptide/
siRNA w/w ratios studied and showed a drop in the ζ-
potential with the highest ratio studied (e.g., −3.90, −0.58,
−6.77, and −12.40 were recorded as the average ζ-potential at
diﬀerent N/P ratios studied). Other modiﬁed cyclic peptides
showed a gradual increase in the ζ-potential; however, they
never achieved any values more than 4.5 (ζ-potential = 4.22 for
Figure 4. Serum stability of siRNA after complex formation. Representative image of gel electrophoresis and a bar graph summarizing the percentage
of intact siRNA after 24 h of exposure to serum at 37 °C for linear (A) and cyclic (B) peptide/siRNA complexes at peptide/siRNA w/w ratios of
2.5−10 and 20−80, respectively. PC and NC represent positive control (scrambled siRNA exposed to saline for 24 h at 37 °C, quantiﬁed as 100%)
and negative control (representing “naked” siRNA incubated with serum for 24 h at 37 °C), respectively. Linear and cyclic peptides conjugated with
C16 and C18 fatty acids as well as the unconjugated cyclic peptide showed the most protection against enzymatic degradation of siRNA. Data are
presented as mean, n = 3, and the error bars represent standard deviation.
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Figure 5. Safety proﬁles of the peptide libraries and the peptide/siRNA complexes in human cell lines. The viability of MDA-MB-231 (A) and MDA-
MB-435 (B) cell lines after 72 h of exposure to diﬀerent peptide concentrations (left panels) and peptide/siRNA complexes in a range of peptide/
siRNA ratios (right panels) are presented for linear (upper panels) and cyclic (lower panels) peptide libraries. Linear peptide conjugated with C12
fatty acid showed the most signiﬁcant toxicity in both cell lines. Data are presented as mean, n = 3, and the error bars represent standard deviation.
The asterisks represent a signiﬁcant diﬀerence (p < 0.05) compared to “no treatment” cells (representing 100% viability; data for which is not
included in the ﬁgure).
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Figure 6. Cellular uptake of FAM-siRNA by human cancer cell lines. The internalization of FAM-labeled siRNA into MDA-MB-231 (the upper
panels in each set) and MDA-MB-435 (the lower panels in each set) cells for linear (left panels in each set) and cyclic (right panels in each set)
peptides is presented as percentage of the cells positive for siRNA uptake (A) and average of the ﬂuorescence in the cell population (B). The cells
were transfected by two diﬀerent peptide/siRNA w/w ratios (20:1 and 40:1 for linear and 80:1 and 120:1 for cyclic peptides). Linear peptide
conjugated with C16 and C18 fatty acids demonstrated the most eﬃcient intracellular siRNA delivery. Data are presented as mean, n = 3, and the
error bars represent standard deviation.
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Figure 7. continued
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CP-C6 at a w/w ratio of 20:1, equivalent to an N/P ratio of
15.3; Figure 3D).
Serum Stability of Complexes. To determine the
capability of the complexes to protect the siRNA against
enzymatic degradation, we exposed diﬀerent study groups to a
diluted FBS solution, with “naked” siRNA as the positive
control and siRNA exposed to saline as the negative control,
and the results are summarized in Figure 4. Although in vitro
experiments are performed in cell culture media containing
10% FBS, a higher concentration of FBS (25%) was used to
determine the stability of siRNA under a harsher condition and
a more biologically relevant environment. After 24 h exposure
to serum, we did not observe any bands for siRNA in the
positive control groups, which indicated complete degradation
of “naked” siRNA under these conditions and validated the
method. Considering the negative control band as 100% intact
siRNA, we calculated the percentage of siRNA that remained
intact in each study group. Although only ∼25% of the siRNA
was protected by the unmodiﬁed linear peptide at the peptide/
siRNA w/w ratio of 10:1, LP-C16 and LP-C18 were able to
protect siRNA almost completely after 24 h of incubation with
the serum in 37 °C. The level of protection was not
signiﬁcantly diﬀerent for the three diﬀerent peptide/siRNA
w/w ratios studied for LP-C18; however, it showed signiﬁcant
improvement for LP-C16 on increasing the w/w ratio from
2.5:1 to 5:1. Other modiﬁed linear peptides showed minimum
to no protection against enzymatic degradation (Figure 4A).
The cyclic unmodiﬁed peptide, on the other hand, showed
signiﬁcant protection that approached 100% on increasing the
peptide/siRNA w/w ratio to 80:1. The only modiﬁed peptides
Figure 7. Eﬀect of incorporation of DOPE in the siRNA complexes on siRNA intracellular delivery. The cellular uptake studies were repeated with
selected peptides to investigate the eﬀect of addition of an additional lipophilic component, and the results are presented as the average of quantiﬁed
ﬂuorescence (A) and percentage of the cells positive for FAM-labeled siRNA uptake (B). Addition of DOPE to the siRNA complexes enhanced
intracellular delivery of siRNA signiﬁcantly for most of the selected peptides. Data are presented as mean, n = 3, and the error bars represent standard
deviation. The asterisks indicate signiﬁcant diﬀerence in cellular internalization as a result of DOPE incorporation into each complex. DOPE (low)
and (high) indicate the siRNA uptake of the cells exposed to complexes of siRNA and DOPE (with no peptide) using the lowest (for complexes with
peptide/siRNA w/w ratio of 20:1 and the highest (for complexes with peptide/siRNA w/w ratio of 120:1) DOPE ﬁnal concentration used in the
other study groups included in the experiment. (C) Samples of ﬂow cytometry results for siRNA uptake: the uppermost row represents the
ﬂuorescence pattern of cells transfected with linear peptide/siRNA w/w ratio of 20:1 or 40:1, with or without DOPE incorporated into the carrier.
The middle and bottom rows represent samples of ﬂuorescence pattern of cells transfected with cyclic peptide/siRNA w/w ratio of 80:1 or 120:1,
with or without DOPE. The gate P2 represents ﬂuorescence of cells considered siRNA-free, whereas the cells in the P3 region are positive for siRNA
uptake. (D) Fluorescent microscope images showing individual channels (green, blue, and red), and an overlay for each treatment group as well as
“No treatment” cells as the negative control.
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that showed noticeable protection against enzymatic degrada-
tion were CP-C16 and CP-C18, with 48 and 35% intact siRNA
detected after incubation of the complexes formed at a peptide/
siRNA ratio w/w of 80:1 (Figure 4B).
Cytotoxicity. The eﬀect of peptide libraries on the viability
of human cell lines was evaluated using two approaches:
exposing the cell lines to diﬀerent concentrations of peptide
solution and exposing the cells to peptide/siRNA complexes
prepared with diﬀerent peptides at various peptide/siRNA
ratios. We duplicated this study in human cancer cell lines
MDA-MB-231 and MDA-MB-435 (Figure 5). The viability of
cells followed a similar pattern after exposure to peptide
solutions and peptide/siRNA complexes in both the cell lines.
In MDA231 cells, LP-C12 showed signiﬁcant cytotoxicity at a
peptide/siRNA w/w ratio of 20:1 (N/P ratio of 23.3), both
alone and incorporated in the siRNA complex. Some toxicity
was also observed with LP-C16 and LP-C18 at this peptide/
siRNA ratio, which was more signiﬁcant with the peptide/
siRNA complexes for LP-C16 (52.9% viability after peptide
exposure vs 35.8% after peptide/siRNA exposure). Interest-
ingly, a similar toxicity was not observed for C12-conjugated
cyclic peptide in this cell line; however, a similar toxicity was
observed for CP-C16 both as peptide solution and peptide/
siRNA complex (Figure 5A). LP-C12, LP-C16, and LP-C18
showed similar toxicity levels in MDA-MB-435 cells as well. For
some of the fatty acid-conjugated cyclic peptides, however, the
toxicity was more signiﬁcant when the MDA-MB-435 cells were
treated with peptide/siRNA complexes as compared to the
peptide solution (68.6% vs 50.1% viability for CP-C12, 77.5%
vs 52.4% viability for CP-18; Figure 4B). The other peptides
showed minimum or no signiﬁcant toxicity in any of the study
groups in either of the cell lines.
Cellular Internalization. The ability of peptide libraries to
deliver siRNA into the cells was evaluated using FAM-labeled
scrambled siRNA and analysis by ﬂow cytometry and
ﬂuorescent microscopy. The siRNA uptake pattern was similar
for both MDA-MB-231 and MDA-MB-435 cell lines. The
internalization of siRNA was minimum with most of the linear
library in both cell lines. However, LP-C16 and LP-C18 were
exceptions and showed a signiﬁcant siRNA uptake, which was
signiﬁcantly higher at a peptide/siRNA ratio of 20:1 (N/P
ratios of 21.6 and 20.8, respectively) compared to the ratio of
10:1 (N/P ratios of 10.8 and 10.4, respectively) (43.8 vs 17.1%
siRNA-positive cells for LP-C16 and 52.4 vs 19.1% for LP-C18)
in MDA-MB-231 cells. The siRNA internalization followed a
similar trend in MDA-MB-435 cells for these two modiﬁed
linear peptides; however, a higher level of eﬃciency was
achieved for LP-C16 at both peptide/siRNA ratios studied
compared to the MDA-MB-231 cells (82.3% vs 43.8% siRNA-
positive cells at a w/w ratio of 20:1 [N/P ratio of 21.6] and
48.7% vs 17.1% at a ratio of 10:1; Figure 6A, left panels).
However, a diﬀerent pattern was observed for cyclic peptides.
None of the cyclic peptides achieved siRNA internalization in
more than 20% of the cells in either of the cell lines included in
Figure 8. Quantiﬁcation of downregulation of mRNA levels of selected targeted proteins. MDA-MB-231 cells were treated with peptide/siRNA
complexes with peptide/siRNA w/w ratios of 40:1 and 120:1 for linear and cyclic peptides, respectively, while the eﬀect of incorporation of DOPE in
the delivery system was also evaluated. Lipofectamine 2000 (Lipo.) was used as the positive control. The mRNA levels of KSP (A) and JAK2 (B) was
quantiﬁed after 48 h of exposure to siRNA complexes using quantitative PCR. Data are presented as mean of RQ compared to cells exposed to saline
(normalized using mRNA levels of β-actin), n = 3, and the error bars represent standard deviation. The asterisks identify the study groups that
demonstrated a signiﬁcant increase in silencing eﬃciency as a result of DOPE incorporation. DOPE (low) and (high) indicate the siRNA uptake of
the cells exposed to DOPE (with no peptide) using the lowest and highest DOPE ﬁnal concentrations used in the other study groups included in the
experiment. (C) Correlation between silencing eﬃciency for the two selected targets: RQs presented in (A) and (B) are plotted on x and y axes,
respectively, and the correlation factor (R) was calculated. The silencing data show signiﬁcant correlation (p < 0.01) between the two selected
targets.
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the study. In the MDA-MB-231 cells, CP-C18, CP-C16, and
CP-C8* internalized siRNA into 12.5, 11.7, and 9.8% of the
cells, respectively, at a peptide/siRNA w/w ratio of 120:1 (N/P
ratios of 126, 131, and 154, respectively). The level of siRNA
uptake was slightly higher in MDA-MB-435 cells, and the same
peptides achieved 19.3, 14.9, and 14.2% siRNA-positive cells at
the same ratios(Figure 6A, right panels). The mean
ﬂuorescence results conﬁrmed a similar pattern in both cell
lines (Figure 6B). The siRNA uptake with other peptides was
not statistically diﬀerent from “naked siRNA”.
To enhance the siRNA internalization capacity, we added
another lipophilic component to the delivery system and
compared the siRNA uptake in MDA-MB-231 cells with and
without incorporating 1,2-dioleoyl-sn-glycero-3-phosphoetha-
nolamine (DOPE) in selected peptide/siRNA complexes using
peptide/siRNA w/w ratios of 20:1 and 40:1 for linear peptides
and 80:1 and 120:1 for cyclic peptides (Figure 7A,B). The
addition of DOPE to the delivery system increased the siRNA-
positive cells from 53 to 96% and from 85 to 98% for 20:1 and
40:1 ratios of LP-C16/siRNA (N/P ratios of 21.6 and 43.2),
respectively. A similar increase (from 51 to 78%) was observed
for the LP-C18/siRNA w/w ratio of 20:1 (N/P ratio of 20.8).
The increase was not statistically signiﬁcant for the w/w ratio of
40:1 (N/P ratio of 41.6) for this peptide (82−84%; Figure 7B).
The role of DOPE in improving the delivery performance of
the selected linear peptides, however, was more noticeable with
analyzing the mean ﬂuorescence of the cells treated with
peptide/DOPE/siRNA complexes. The mean ﬂuorescence of
the treated cells increased from 281 to 3693 and from 893 to
11 861 for LP-C16/siRNA w/w ratios of 20:1 and 40:1,
respectively. A similar pattern was observed for the LP-C18-
modiﬁed peptide (increasing the mean ﬂuorescence from 329
to 5040 and from 824 to 1855 for ratios of 20:1 and 40:1,
respectively, Figure 7A). Diﬀerent fatty acid-conjugated cyclic
peptides responded slightly diﬀerently to DOPE addition.
Whereas CP-C4, CP-C10, and CP-C18 demonstrated a
signiﬁcant increase in the percentage of cells internalizing
siRNA at both peptide/siRNA ratios, CP-C16 only showed a
signiﬁcant improvement in eﬃcacy with DOPE addition at a w/
w ratio of 120:1 (N/P ratio of 131) (at a w/w ratio of 80:1 [N/
P ratio of 87.4], 17.6 and 17.1% of cells internalized siRNA with
and without DOPE addition to the delivery system). Adding
DOPE did not improve siRNA delivery at either of the ratios
for CP-C8* (Figure 7B). Mean ﬂuorescence results conﬁrmed
the same trends for cyclic peptides, except CP-C16, which
showed a signiﬁcant improvement in siRNA internalizing
eﬃciency at a CP-C16/siRNA w/w ratio of 120:1 (582−1016
without and with DOPE, respectively, Figure 7A). Delivering
FAM-labeled siRNA using only DOPE (with no peptide) with
the lowest and highest ﬁnal concentration used in this study did
not result in a signiﬁcant cellular internalization of siRNA.
Figure 7C illustrates examples of the ﬂuorescence recordings of
ﬂow cytometry for diﬀerent peptides with and without DOPE
compared to nontreated (NT) cells. The ﬂuorescent micro-
scope images conﬁrmed our ﬁndings using ﬂow cytometry.
Although DOPE/FAM-labeled siRNA did not show any
internalization into MDA-MB-231 cells, both LP-C16 and
LP-C18 peptides demonstrated cell uptake that increased
signiﬁcantly with the addition of DOPE.
Silencing Eﬃciency. Two model proteins were selected to
demonstrate the in vitro silencing eﬃciency of the designed
modiﬁed peptides. LP-C16, LP-C18, CP-C4, CP-C10, CP-C16,
and CP-C18 were selected for delivering siRNAs targeting
kinesin spindle protein (KSP) or Janus kinase 2 (JAK2), and
the mRNA levels were directly compared to cells treated with
scrambled siRNA. Each peptide was tested with and without
incorporation of DOPE into the carrier. Between the selected
linear peptides, LP-C18 showed a higher eﬃciency [relative
quantity (RQ) of 0.52 compared to 0.79 for LB-C16] in
silencing KSP (Figure 8A). The eﬃciency diﬀerence between
the two peptides was not as much against JAK2 (0.55 vs 0.65;
Figure 8B). None of the cyclic peptides showed an RQ lower
than 0.75 for KSP without DOPE. However, delivering JAK2
siRNA, CP-C18 demonstrated an RQ of ∼0.7. Overall, without
adding DOPE to the carriers, the highest silencing eﬃciency
was achieved with the selected linear peptides delivering JAK2
siRNA. Incorporating DOPE to the carrier had a similar
enhancing eﬀect observed in cellular internalization studies. All
selected peptides (except CP-C16) showed a higher silencing
eﬃciency against both selected proteins with the addition of
DOPE. The DOPE enhancing eﬀect was more noticeable in
silencing KSP, where the CP-C10 (0.47 with DOPE vs 0.97
without it), LP-C16 (0.40 with DOPE vs 0.79 without it), and
LP-C18 (0.18 with DOPE vs 0.53 without it) showed the most
signiﬁcant response to the addition of DOPE to the delivery
system.
Overall, with the addition of DOPE, the highest silencing
eﬃciency against KSP and JAK2 was achieved by LP-C18 (RQ
of 0.18) and LP-C16 (RQ of 0.32), respectively (Figure 8A,B).
DOPE alone (with no peptide) did not induce signiﬁcant
silencing for either of the selected proteins, even with the
highest ﬁnal concentration of DOPE used in this study. The
silencing eﬃciency of delivered siRNA against KSP and JAK2
showed a strong correlation (R = 0.82; p < 0.01), as illustrated
in Figure 8C.
■ DISCUSSION
The therapeutic possibilities with RNAi via siRNAs have not
been utilized to the full potential, mostly because of the
underperformance of the carriers. Cationic lipids or polymers
are among the commonly studied nonviral carriers for nucleic
acids because of their spontaneous tendency to interact with
the cargo via interionic interaction. Neutralization of the siRNA
electric charge in the process also enhances cell internalization
by compacting nucleic acid and reducing the hydrophilicity of
this type of molecule. Short (around 30 amino acids or less)
CPPs have also been used as an alternative approach, either by
covalently binding the peptide to siRNA or by complex
formation using positively charged peptides.2 In 2013, van
Asbeck et al. reported a study on siRNA complex formation
with a small library of arginine- or lysine-rich linear peptides
and demonstrated that using a stearyl group to replace the
acetyl group could enhance the silencing eﬃciency against the
luciferase reporter gene in a leukemia cell line,21 which the
authors contributed to induced amphipathic characteristics. In
this study, we used a variety of fatty acids with a wide range
(C2−C18) to modify linear and cyclic peptides composed of
ﬁve arginine and two lysines.
Herein, we designed two libraries of linear and cyclic
peptides with similar amino acid compositions and studied the
eﬀect of hydrophobic modiﬁcation of synthesized peptides with
fatty acids with a wide range of chain lengths. We hypothesized
that the cyclic structure of the second library could oﬀer higher
cell-penetrating ability and stability and less toxicity over linear
counterparts. In our synthesized peptides, no inter- and/or
intra-dicarboxylate cross-linked products were observed
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because 3 equiv of fatty acids was used in the coupling reactions
in a very dilute solution in DMF that minimizes coupling of
both carboxylic acids in each fatty acid in the intramolecular or
intermolecular reactions. Furthermore, all ﬁnal products were
puriﬁed by HPLC as described in the manuscript. MALDI
spectral data did not exhibit the presence of intermolecular or
intramolecular products.
To evaluate the ability of synthesized peptides to bind to
siRNA, we performed a binding assay we had previously
reported using the SYBR Green dye to quantify the free
siRNA.22 Among the linear-modiﬁed peptides, LP-C2, LP-C4,
LP-C6, and LP-C10 did not achieve a complete siRNA binding
in the range of peptide/siRNA w/w ratio studies. In addition to
a relatively smaller fatty acid conjugation, these peptides have
another common characteristic, the dicarboxylic conjugated
fatty acid, which means a −COOH group that exists at the free
end of the fatty acid could be partially ionized in a neutral pH
and create a negatively charged group. This ionization could
potentially interfere with the interionic interaction with
negatively charged siRNA and therefore limit the extent of
binding. The only other linear peptides conjugated with
dicarboxylic fatty acids in the library is LP-C8, which
demonstrated one of the highest BC50 values among the
linear peptides that achieved complete binding. Cyclic peptides
showed a higher BC50. In fact, in addition to the unmodiﬁed
cyclic peptide, only CP-C8*, CP-C10, CP-C12, and CP-C18
showed complete binding at the highest peptide/siRNA w/w
ratio studied (80:1) (Figure 2). Cyclic peptides are more rigid
and expected to be more stable toward degradation. However,
this rigidity of the molecular structure could hinder the
interionic interaction with siRNA molecules, which could
explain the higher BC50 for this library. A signiﬁcant
correlation between the BC50 values and the length of the
conjugation was not observed for either of the libraries (data
not shown).
Difatty acyl peptide conjugates have diﬀerent physicochem-
ical properties. A number of factors are involved in interactions
with siRNA, such as charge, hydrophobicity, size, overall
structure, and conformation of the conjugates. The level of
hydrophobicity/charge ratio is a key factor for the binding of
amphiphilic conjugates to siRNA. The chain length and its
ﬂexibility are postulated to generate highly condensed positively
charged amphiphilic particles for eﬃcient interactions with
siRNA. However, our data indicate that the enhanced
hydrophobicity of the delivery system (both by increasing the
chain length in the fatty acid structure and by addition of
DOPE as an extra hydrophobic component) plays a signiﬁcant
role in the level of interaction of the delivery system with the
cell membrane.
The size and electric surface charge of siRNA carriers are
crucial characteristics for the eﬃciency of delivery, and we used
a Zetasizer to analyze both the hydrodynamic diameter and ζ-
potential of the peptide/siRNA complexes. The ability of a
carrier to condense the nucleic acid cargo is considered one of
the important factors in protecting siRNA and internalizing it
into the target cells.23 We observed a gradual decrease in the
particle size of the complexes with increasing peptide/siRNA
w/w ratio from 1:1 to 20:1 for most of the synthesized peptides
(Figure 2A,B), which could indicate complex formation. Most
of the complexes showed a particle size of less than 200 nm,
which is considered the proper size for in vitro siRNA
delivery.24 We previously reported a similar range of particle
sizes for hydrophobically modiﬁed low-molecular-weight
polyethyleneimine (PEI),22 which was shown eﬀective for in
vitro and in vivo delivery of siRNA to a variety of cell lines.25,26
The presence of a positive surface charge seems to be
important for the cellular uptake and limits the risk of particle
aggregation. It has been suggested that a slightly positive
surface charge (+2 to +10) is the ideal surface charge to
optimize cell surface interactions while minimizing nontarget
carrier binding.27,28 The ζ-potential of siRNA complexes is
expected to move toward positive values as the peptide/siRNA
ratio is increased. This gradual increase was observed for most
of the linear peptides (except LP-C4 and LP-C14, which
showed negative values for the peptide/siRNA w/w ratio of
20:1) and a few of the cyclic peptides (Figure 3C,D). A
negative value suggests incomplete binding, which conﬁrms our
observations in the binding study.
One of the major hurdles in siRNA delivery is the
susceptibility to enzymatic degradation, which limits siRNA in
vivo half-life to a few minutes.29 A gel electrophoresis method
was used to quantify intact siRNA after exposure of peptide/
siRNA complexes to serum. Whereas positive and negative
controls conﬁrmed the validity of the method, most of the
peptides failed to protect siRNA for 24 h. Only C16- and C18-
conjugated peptides showed protection against enzymatic
degradation, which could be due to the maximum hydro-
phobicity of these modiﬁed peptides. This protection
potentially limits the interaction of siRNA with the enzymatic
components in the aqueous surrounding medium (Figure 4). A
near complete protection was also provided by the unmodiﬁed
cyclic peptide, which could be explained by the high aﬃnity for
siRNA binding (the highest among the cyclic library) and a
small positive ζ-potential at a ratio of peptide/siRNA ratio of
20:1 (N/P ratio of 44.7). Higher peptide/siRNA w/w ratios
were used for the cyclic library (up to 80:1) because of limited
serum stability and BC50 observed in this study and previous
experiments.
We selected two approaches to evaluate the toxicity of the
delivery system: exposure of the cells to diﬀerent concen-
trations of peptides and treatment with peptide/scrambled
siRNA with corresponding peptide concentrations. Both
approaches were evaluated based on the speculations that
positively charged carriers enhance cellular uptake via the whole
formation in the cell membrane.30 Because complex formation
changes the overall charge of the peptide, the cytotoxicity of the
peptide alone and as a complex with siRNA could potentially
be diﬀerent. LP-C12 showed an unusual toxicity compared to
other synthesized peptides in both cell lines used (Figure 5).
LP-C16 and LP-C18 were the other peptides that showed a
higher toxicity compared to other peptides in the highest
concentration examined. Whereas the higher toxicity of the
C16- and C18-conjugated peptides could be explained by a
closer interaction with the cell membrane because of increased
hydrophobicity of the peptide, the unusual toxicity of LP-C12
might be due to an incomplete puriﬁcation process that could
expose the cells to impurities remaining in peptide solution.
The trend of toxicity was similar for both approaches, which
indicates that the toxicity mechanism might be independent of
the electrical charge of the peptide. Most synthesized peptides
were nontoxic in the selected concentration range, and overall,
the cyclic library was less toxic than the linear equivalents.
In general, conjugation with C18* demonstrated a safer
toxicity proﬁle compared to conjugation with C18. Whereas
these two conjugations showed a comparable safety proﬁle for
the cyclic peptide in MDA-MB-231 cells, LP-C18 and CP-C18
ACS Omega Article
DOI: 10.1021/acsomega.7b00741
ACS Omega 2017, 2, 6939−6957
6951
showed a more signiﬁcant eﬀect on cell viability in both
selected cell lines both as peptide alone (in the concentration
range of 5−20 μg/mL) and as a peptide/siRNA complex,
especially at peptide/siRNA w/w ratios of 20:1 and 40:1,
compared to LP-C18* and CP-C18*, respectively. These
diﬀerences suggest that the conjugation of the peptide with
unsaturated linoleic acid in C18* (compared to saturated
stearic acid in C18) reduces the interaction with the cell
membrane, which was conﬁrmed by a signiﬁcantly higher
cellular internalization in the subsequent experiments for C18.
The cytotoxicity data also indicated an unusual toxicity for LP-
C12, which was not seen in the cyclic peptide counterpart. This
might be an indication of an impurity in the synthesis product
that was not detected in our analysis of the peptide. However,
we did not investigate this unusual eﬀect further because LP-
C12 did not show promising siRNA delivery characteristics in
the selected cell lines.
Our cellular internalization studies conﬁrmed our results
from our particle characterization studies. Linear peptide
conjugated with C16 and C18 fatty acids showed the highest
eﬃciency in internalizing FAM-labeled siRNA into both human
cancer cell lines studied. The average ﬂuorescence signal,
however, was signiﬁcantly higher in MDA-MB-231 triple-
negative breast cancer cells (Figure 6B). This was surprising
because in one of our previous studies, we observed the
opposite (more eﬃcient delivery to MDA-MB-435 cells using
fatty acid-conjugated low-molecular-weight PEI).26 The average
ﬂuorescence signal and the percentage of cells showing siRNA
uptake were both lower for the cyclic peptides. CP-C16 and
CP-C18 showed the highest delivery eﬃciency in this library.
This was not surprising because we perform our uptake studies
in serum-rich media, and the binding aﬃnity, ζ-potential of
complexes, and protection against enzymatic degradation all
play important roles in the cellular internalization of siRNA.
Whereas the cyclic peptide library showed an overall lower
aﬃnity to bind to siRNA and demonstrated a lower ζ-potential
for most of the cyclic peptides and a lower serum stability of
siRNA, only the most hydrophobic cyclic peptides (C16- and
C18-conjugated peptides) showed some promising results in
those characterization experiments. Noticing the role of
hydrophobicity of the carriers in internalizing siRNA, we
repeated the cell internalization study with selected peptides,
adding a new hydrophobic component to the delivery system.
DOPE has been commonly used as a component in diﬀerent
liposomal and polymeric siRNA delivery systems.31−34 We
investigated the eﬀect of incorporating DOPE into the peptide/
siRNA complexes and used DOPE/siRNA as a control group
to evaluate the eﬀect of DOPE alone in siRNA delivery. In our
studies, DOPE did not show a signiﬁcant siRNA uptake;
however, the addition of DOPE to peptide/siRNA complexes
had a signiﬁcant eﬀect on the siRNA delivery eﬃciency of all
selected peptides (except caprylic acid-conjugated cyclic
peptide and CP-C16 at the lower selected peptide/siRNA
ratio). The enhancing eﬀect of DOPE was speciﬁcally
signiﬁcant on LP-C16, where the average of the ﬂuorescence
signal increased more than 10-fold (from 893 to 11861) for a
peptide/siRNA w/w ratio of 40:1 (N/P ratio of 43.2) (Figure
6). Lipids have been extensively used as the individual carrier of
siRNA (cationic lipids as lipoplexes) or as a hydrophobic
modiﬁer or component in other delivery systems. It is
speculated that they enhance cellular internalization by
enhancing the interaction of the particle with the cell
membrane, which in turn could trigger a cellular uptake. On
the basis of observations on the eﬀect of fatty acid chain length
on the eﬃciency of siRNA delivery, we believe this hydro-
phobic interaction is the main mechanism involved in the
internalization of these particles. Our microscopic images
(Figure 7D) conﬁrmed the impact of DOPE addition to the
delivery system.
Cell internalization of siRNA is only the ﬁrst step in protein
silencing. The ability to escape endosomes and the timely
release from the complexes are the other necessary steps in
successful mRNA targeting and degradation. To demonstrate
the silencing eﬃciency of our hydrophobically modiﬁed
peptides, we targeted two unrelated proteins that have been
extensively studied for their roles in cell proliferation and
survival. KSP is a member of kinesin superfamily of microtubule
motors involved in mitosis and has been targeted by small-
molecule drugs35,36 and siRNA37,38 as an anticancer strategy.
JAK2, on the other hand, is a pivotal component of the JAK/
STAT pathway that has been studied extensively for its key role
in development, proliferation, diﬀerentiation, and survival of
cancer cells.39 JAK inhibitors, for example, ruxolitinib and
tofacitinib, are used in clinics.40 We have previously reported
JAK2 silencing via siRNA delivery and its impact on inhibiting
the growth of human cancer cells.25,26,41 Our silencing
experiments in this project conﬁrmed our observations in the
cell internalization studies. Whereas C16- and C18-conjugated
peptides (especially linear peptides) showed silencing against
both the targeted proteins, the addition of DOPE enhanced the
silencing eﬃciency signiﬁcantly for all selected peptides, except
CP-C16. This is consistent with our observations in the uptake
study and conﬁrms that the addition of DOPE not only
increases the cellular uptake but this uptake also translates to
eﬃcient protein silencing. Maybe even more signiﬁcantly, the
signiﬁcant correlation between the silencing eﬃciency against
two selected proteins indicates the eﬃciency of this approach
regardless of the expression level of the targeted protein or its
role in intracellular mechanisms. Our experiments also
demonstrated a silencing eﬃciency that was comparable, and
even superior in some cases, to commercially available
Lipofectamine 2000. Whereas the RQ of ∼0.5 was observed
for siRNAs delivered by Lipofectamine, LP-C18 reduced the
mRNA levels of KSP and JAK2 to RQs of 0.18 and 0.32,
respectively (Figure 8).
These data indicate that an optimal fatty acyl chain length is
required for eﬃcient interaction with the cell membrane and
internalization, as observed for both cyclic and linear peptides.
The difatty acyl linear peptides, LP-C16 and LP-C18, are more
eﬃcient siRNA carriers when compared with the corresponding
difatty acyl cyclic peptides, CP-C16 and CP-C18, possibly
because of the more eﬃcient interactions of positively charged
amino acids and fatty acyl chains with the cell membrane and
siRNA in more ﬂexible linear conjugates versus the cyclic ones.
It was also noticed that the presence of more rigid unsaturated
linoleic acid in both LP-C18* and CP-C18* signiﬁcantly
reduced siRNA stability and siRNA internalization when
compared with the corresponding more ﬂexible stearic acid
analogues LP-C18 and CP-C18 peptides, respectively. These
data indicate that the fatty acid chain length and peptide and
fatty acid ﬂexibility are the determinant factors for optimal
interactions with the membrane and siRNA and cellular
internalization.
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■ CONCLUSIONS
Peptides have shown promising eﬃciency as cell-penetrating
components in siRNA delivery. We hypothesized that
synthesizing hydrophobically modiﬁed cationic peptides can
be an eﬀective approach in forming stable complexes with
siRNA that are capable of internalizing into the target cells and
target any mRNA in the cytoplasm. Our results showed that the
level of hydrophobicity is a key factor in the eﬃciency of the
carriers. In fact, the addition of an extra hydrophobic element
signiﬁcantly enhanced the performance of designed peptides as
shown in C16 and C18 peptides. This study reveals the
promising potential of a number of peptide/lipid nanoparticles,
such as C16 and C18 peptides, for eﬀective siRNA delivery that
justiﬁes further evaluation in vivo.
■ EXPERIMENTAL SECTION
Materials. For the list of materials used in this project,
please see the Supporting Information.
Methods. Assembly of Amino Acids on Resins for the
Synthesis of Resin-Attached Linear and Cyclic Peptides. The
synthesis of R5K2 peptides was achieved by using 0.50 mmol
Fmoc-L-Arg(Pbf)-Wang or H-Arg(Pbf)-2-ClTrt resins for
linear and cyclic peptides, respectively. The resin was added
to a reusable fritted glass reaction vessel and placed on the
Tribute peptide synthesizer. Each vial was ﬁlled with 3 equiv of
amino acids (Fmoc-Arg(Pbf)-OH and Fmoc-Lys(Dde)-OH for
linear peptides and Fmoc-Arg(Pbf)-OH and Fmoc-Lys(Boc)-
OH for cyclic peptides) and 2.5 equiv of HBTU as the coupling
reagent. All of the solvent bottles were pressurized with
nitrogen, while the reaction vessel was also pressurized and
mixed by the nitrogen inlet and was vacuum-sealed. The
deprotection of the Fmoc group was performed by addition of
piperidine in DMF (20 v/v %). The program conﬁgured to
remove the Fmoc-protecting group of the resin-attached amino
acid before coupling the ﬁrst amino acid residue. Once the ﬁrst
amino acid residue was coupled, the remaining residues were
added to the reaction vessel by single coupling. The poor
coupling of the hydrophobic fatty acids for linear and cyclic
peptides was mostly likely because of some aggregation,
possibly due to the interactions between hydrophobic residues
during the fatty acid coupling. To overcome the aggregation,
double-coupling was used for the linear peptide fatty acid
conjugation. In regard to the fatty acid conjugations for the
cyclic peptide, the reactions were performed under solution
phase air-free peptide synthesis. A percentage yield of
approximately 60−70% was observed for most of the linear
peptide compared to 40−50% for cyclic peptide conjugations.
Synthesis of Difatty Acyl Linear Peptide Conjugates.
Fmoc-protecting group was removed from the Fmoc-L-
Arg(Pbf)-Wang resin (0.50 mmol) in the presence of
piperidine in DMF (20 v/v %). For the synthesis of linear
peptides with capped N-acetyl amino group (LP-C2 and LP-
C4), two Fmoc-Lys(Dde)-OH amino acids were used in
coupling; then, the N-terminal Fmoc group was removed ﬁrst
in the presence of piperidine (20%) in DMF followed by
capping with acetic anhydride before removal of the Dde group
and fatty acid (C2 or C4) conjugation as described below. For
the remaining linear peptides, two kinds of lysines were used:
Fmoc-Lys(Dde)-OH and Boc-Lys(Fmoc)-OH. The Boc group
was removed after the fatty acid conjugation described below
and after the ﬁnal cleavage. Once the peptide sequence was
assembled on the resin and completed by the Tribute, the side
chain Dde of the ﬁrst lysine and the Fmoc group of the second
lysine were removed by addition of hydrazine (2%, 1 mL) and
DMF (98%, 49 mL). The mixture of 2% hydrazine was mixed
with the resin for 2 h at room temperature under nitrogen. The
resin was drained and washed with DMF three times (3 × 3
mL). The coupling of the fatty acid was carried out after the
deprotection of lysines. The reaction was accomplished by
mixing 3 equiv of the fatty acid with 2.5 equiv of HBTU and 6
equiv of DIPEA in DMF. The fatty acid coupling was repeated
to ensure maximum coupling to the unprotected peptide. The
fatty acids used for both libraries included acetic anhydride
(C2), succinic acid (C4), adipic acid (C6), suberic acid (C8),
caprylic acid (saturated eight carbon chain, C8*), sebacic acid
(C10), lauric acid (C12), myristic acid (C14), palmitic acid
(C16), stearic acid (C18), and linoleic acid (unsaturated 18
carbon chain, C18*). The ﬁnal cleavage of the linear peptide
was performed by adding a cocktail of TFA, anisole, thioanisole,
and DTT. A cleavage cocktail (20 mL) was prepared by adding
18 mL of TFA, 0.50 mL of anisole, 0.50 mL of thioanisole, and
50 mg of DTT, and it was added to the linear peptide
assembled on the Wang resin. The mixture was then stirred for
4 h to aﬀord crude difatty acyl linear peptide conjugates.
Synthesis of Difatty Acyl Cyclic Peptide Conjugates. H-
Arg(Pbf)-2-ClTrt (0.5 mmol) was swelled in DMF. Fmoc-
Arg(Pbf)-OH and Fmoc-Lys(Boc)-OH were used as building
blocks. After assembly of the peptide sequence, the cleavage of
the peptide from the 2-chlorotrityl resin was performed
manually from the resin with acetic acid/triﬂuoroethanol/
DCM (1:2:7 v/v/v) for 2 h at room temperature. The solution
was ﬁltered and washed with DCM to remove acetic acid. The
cleavage solution was diluted with n-hexane and evaporated
four times. The remaining acetic acid was evaporated overnight
by vacuum. To cyclize the peptide, HOAT (122.50 mg, 0.3
mmol, 3 equiv) was added to the dried linear peptide in a 500
mL ﬂask. The mixture of DCM and DMF (1:4) was added to
the ﬂask, followed by addition of 140 μL of N,N′-
diisopropylcarbodiimide into the solution under dry nitrogen.
The reaction was continued for 24 h to complete. Once the
cyclization was complete, deprotection was carried out with
reagent R (TFA/anisole/thioanisole/DTT), followed by the
coupling of fatty acid in the presence of HBTU and DIPEA,
according to the method described above for linear peptides.
The same selected fatty acids that were used for the generation
of the difatty acyl linear peptide library were also utilized to
aﬀord the crude difatty acyl cyclic peptide conjugates.
Analysis and Puriﬁcation Method. All of the crude peptide
fatty acid conjugates were puriﬁed by using the preparative
HPLC to achieve the minimum purity of 90%. The dicarboxylic
fatty acid cyclic and linear conjugates were dissolved in 2:1
water/acetonitrile (v/v), and the solution was ﬁltered before
injection to the HPLC. The HPLC system included an XBridge
BEH130 reversed-phase C18 column (19 × 250 mm, 10 μm
particle size, Waters Corp., Milford, MA, USA) maintained at
50 °C, LC-20AD pumps (Shimadzu Corp., Kyoto, Japan), an
FRC-10A fraction collector, and an SPD-M20A diode array
detector. For shorter chain difatty acyl conjugates, gradient
elution was performed at a ﬂow rate of 10 mL/min with mobile
phase composition ranging from 95:5 water/acetonitrile (v/v)
to 5:95 water/acetonitrile (v/v) throughout the 60 min run.
The mobile phase contained 0.1% TFA throughout the
gradient. Hydrophobic difatty acyl peptides, containing longer
fatty acid chains, were dissolved in a mixture of methanol/
isopropanol alcohol (1:1, v/v), and a gradient system of
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methanol/isopropanol alcohol with 0.1% TFA was used for
dilution. The detector monitored the absorbance of the amide
bond at the given wavelength of 215 nm.42,43 Mass spectra were
collected from m/z 900 to 3500 using the positive reﬂective
mode of MALDI mass spectrometer to characterize the
molecular weight, using freshly prepared α-cyano-4-hydrox-
ycinnamic acid (5 mg/mL) in acetonitrile (0.1% TFA) and
water (0.1% TFA) (1:1, v/v) as the matrix. Using the
FlexControl software (Bruker Corp.), the retention times for
the peak tops of the chromatograph were determined from the
ion chromatograms of the protonated difatty acyl peptide
conjugates. MALDI-TOF mass spectrometry data for difatty
acyl linear and cyclic peptides are shown in Table S1
(Supporting Information).
Complex Formation with Modiﬁed Peptides and siRNA.
The peptide/siRNA complexes were formed in diﬀerent w/w
ratios for the variety of in vitro studies conducted for this
project. The complexes formed spontaneously based on the
ion/ion interaction in normal saline. For each formulation, the
required amount of siRNA stock solution (10 μM) was added
to normal saline, and then the calculated amount of peptide
stock solution (1 mg/mL) was added to the solution. The
mixture was gently mixed and was incubated at room
temperature for 30 min to ensure complete complexation.
The peptide/siRNA ratios used in complex formations are
reported as weight/weight ratios as well as N/P ratios. The N/
P ratios were calculated using the following formula
=
# × #
# × #
N/P
of moles of peptide of nitrogens in each molecule of peptide
of moles of siRNA of phosphate groups in each molecule
All siRNAs used in this project contain 21 base pairs in each
strand, with a 2 nucleotide overhang on each strand, which
represents 20 phosphodiester linkages for each siRNA
molecule. The siRNA targeting JAK2 (Qiagen catalogue #
SI02659657) represented the following sequence: sense: 5′-
CCAUCAUACGAGAUCUUAATT-3′; antisense: 5′UUAA-
GAUCUCGUAUGAUGGCT-3′). The sequence for other
siRNAs used in this study was not provided to the authors as
they were considered proprietary information. The number of
protonable nitrogen atoms diﬀered among the peptides, and
the net positive charge varied between 2 and 7. Table S2
summarizes the N/P ratios for some of the w/w ratios reported
in this manuscript.
Amount of Peptide Required for 50% siRNA Binding
(BC50). To evaluate the eﬀect of hydrophobic modiﬁcation of
the linear and cyclic peptides on their ability to bind to siRNA,
a previously reported SYBR Green II dye exclusion assay was
performed using a wide range of N/P ratios. This method has
been extensively used for DNA44 and has been shown to
correlate with the results of the electrophoretic mobility shift
assay for quantiﬁcation of siRNA binding.45 Complexes were
formed using scrambled siRNA and all modiﬁed peptides in
both libraries with N/P ratios up to 8 for linear library and N/P
ratios up to 90 for cyclic library. After completion of complex
formation, SYBR Green II dye solution (1:10 000 dilution in
double-distilled water) was immediately added to each complex
solution, and the ﬂuorescence of the solution was quantiﬁed in
a 96-well plate at a λ excitation of 485 nm and a λ emission of
527 nm. Free siRNA (with similar concentration to complexes)
was used as the control to determine the unbound siRNA in
each complex formulation, using the following equation
= − ×
% siRNA bond to peptide
100 (
fluorescence signal for complex
fluorescence signal for free siRNA
100)
A completely bond siRNA sample was also prepared as a
positive control using a previously reported hydrophobically
modiﬁed, low-molecular-weight PEI.22 To determine the ratio
required for 50% siRNA binding (BC50) for each hydrophobi-
cally modiﬁed peptide, the percentage of siRNA bond to each
peptide versus the peptide/siRNA ratios was plotted, and BC50
was calculated based on the linear portion of the curve for each
experiment.
Light Scattering for Size and ζ-Potential of siRNA
Complexes. The hydrodynamic diameter and surface charge
of the complexes were analyzed using a Malvern Nano ZS
Zetasizer (Westborough, MA) at 25 °C in disposable cuvettes
and folded capillary cells, respectively. The peptide/siRNA
complexes were prepared with a variety of peptide/siRNA w/w
ratios ranging from 1:1 to 20:1 using scrambled siRNA to study
the eﬀect of the composition of the complex on these physical
characteristics. The ζ-potential of the complexes was
determined at 40 V, using Smoluchowski approximation.
Protection of siRNA against Enzymatic Degradation. To
study the capability of the fatty acid-conjugated linear and cyclic
peptides to enhance the stability of siRNA in biological
environments, samples of unprotected scrambled siRNA
(positive control) and peptide/siRNA complexes at diﬀerent
peptide/siRNA ratios, ranging from 2.5:1 to 10:1 for linear and
from 20:1 to 80:1 for cyclic peptides, were exposed to FBS
solutions. After completion of complex formation for each
formulation, each sample was added to a 25 v/v % FBS solution
in Hank’s balanced salt solution (HBSS), and the mixture was
incubated at 37 °C for 24 h. A sample of unprotected siRNA in
HBSS was used as the negative control, representing 100%
intact siRNA. After incubation, the complexes were dissociated
using a 2:3 mixture of heparin (5% solution in normal saline)
and ethylenediaminetetraacetic acid (0.5 mM), and the samples
were analyzed using 1% agarose gel (with 1 μg/mL ethidium
bromide) at 70 V for 20 min. Ultraviolet illumination (Gel-Doc
system, Bio-Rad; Hercules, CA) was used to visualize the gel,
and the intensity of the bands (representing remaining intact
siRNA) was quantiﬁed by Image J software.
Cell Lines. The human breast cancer cell line MDA-MB-231
and the human cell line MDA-MB-435 were purchased from
American Type Culture Collection (ATCC; Manassas, VA).
MDA-MB-231 and MDA-MB-435 were cultured in Dulbecco’s
modiﬁed Eagle’s medium and in Roswell Park Memorial
Institute 1640 medium, respectively. Both media were
supplemented with 10% (v/v) FBS, 100 U/mL penicillin, and
100 μg/mL streptomycin. Cells were maintained under a
normal condition of 37 °C and 5% CO2 under a humidiﬁed
atmosphere and were subcultured when 80−100% conﬂuent.
Toxicity of the Difatty Acyl Peptides and Peptide/siRNA
Complexes. The safety proﬁles of the linear and cyclic peptide
libraries were evaluated in two diﬀerent human cancer cell lines
by exposing the cells to the peptides alone and in peptide/
siRNA complexes. Conﬂuent cultures (∼800 000 cells/mL) of
MDA-MB-231 and MDA-MB-435 human cancer cell lines were
seeded in 96-well plates. After 24 h, the cells were exposed to
diﬀerent concentrations of peptide solutions or peptide/siRNA
complexes. Linear peptide solutions were added to both cell
lines to create ﬁnal concentrations of 2.5, 5, 10, and 20 μg/mL,
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whereas cyclic peptides were added to the ﬁnal concentrations
of 5, 10, 20, and 40 μg/mL. Peptide/siRNA complexes were
prepared with diﬀerent peptide/siRNA w/w ratios of 5:1, 10:1,
20:1, and 40:1 (translating to 2.5, 5, 10, and 20 μg/mL peptide
ﬁnal concentration) for linear and 10:1, 20:1, 40:1, and 80:1
(equivalent to 5, 10, 20, and 40 μg/mL peptide ﬁnal
concentration) for cyclic peptides. The ﬁnal concentration of
scrambled siRNA was 36 nM in all cytotoxicity studies
performed with peptide/siRNA complexes. The cells were
then incubated for 72 h at 37 °C with controlled CO2 and
humidity. A standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide assay was performed after the incubation
period to determine the cell viability as a percentage of NT
cells.
Internalization of siRNA into Human Cancer Cell Lines.
The capability of difatty acyl linear and cyclic peptide libraries
in internalizing siRNA into human cells was evaluated using
FAM-labeled scrambled siRNA and ﬂow cytometry and
ﬂuorescent microscopy. Both MDA-MB-231 and MDA-MB-
435 cell lines were used for these studies and were seeded in
24-well plates (∼200 000 cells per well). Peptide/siRNA
complexes were prepared in ratios of 10:1 and 20:1 for the
linear peptide library and 80:1 and 120:1 for the difatty acyl
cyclic peptide library, with a ﬁnal concentration of 36 nM for
the ﬂuorescent-labeled scrambled siRNA. After addition of the
siRNA complexes to the cell culture media, the cells were
incubated in 37 °C and standard growth conditions for 24 h.
After the incubation period, for ﬂow cytometry studies, the cells
were washed with clear HBSS (×2), trypsinized, and ﬁxed using
3.7% formaldehyde solution. The suspended cells were
analyzed with a BD-FACSVerse ﬂow cytometer (BD
Biosciences; San Jose, CA) using the ﬂuorescein isothiocyanate
(FITC) channel to quantify cell-associated ﬂuorescence. To
investigate the eﬀect of the addition of DOPE to the delivery
system, DOPE was added to the complexes in a peptide/DOPE
molar ratio of 3:2. After each ﬂow cytometry analysis, the
percentage of cells with a ﬂuorescence signal and the mean
ﬂuorescence of the cell population were calculated based on the
calibration of the signal gated with NT cells (as the negative
control), so that the autoﬂuorescence would be ∼1% of the
population.
To obtain ﬂuorescent images of the siRNA cellular uptake,
cells were seeded on a glass slide in a 6-well plate (at ∼400 000
cells/mL), and after 24 h, they were exposed to FAM-labeled
siRNA complexes. After 24 h of exposure to FAM-labeled
siRNA, the cells were washed with clear HBSS and ﬁxed in
3.7% formaldehyde solution for 30 min at room temperature.
The cell membrane and nucleus were stained with Texas Red
Phalloidin (Invitrogen) (1:250 in HBSS) and 4′,6-diamidino-2-
phenylindole (DAPI), respectively. A KEYENCE BZ-X700 all-
in-one ﬂuorescence microscope (KEYENCE Corp. of America,
Itasca, IL) was used to produce ﬂuorescence images using the
40× objective and diﬀerent ﬁlters for DAPI, FITC, and Texas
Red. NT cells were used as negative controls.
In Vitro Silencing of Selected Proteins. The eﬃcacy of
siRNA delivered by selected peptides in silencing speciﬁc
proteins was studied in the MDA-MB-231 cell line. Conﬂuent
cells were seeded in 6-well plates (∼400 000 cells/mL) and
were treated with scrambled siRNA (CsiRNA) or targeted
siRNAs (ﬁnal concentration of 54 nM) delivered with selected
peptides with or without DOPE. After 48 h of incubation at 37
°C and under normal cell culture conditions, the cells were
lysed with TRIzol (1 mL for each 1 × 106 cells) for cDNA
synthesis and real-time polymerase chain reaction (RT-PCR).
The cell lysates were incubated at room temperature for 5 min,
before chloroform (with a 1:5 v/v ratio to TRIzol) was added
to the lysates. The tubes were mixed and incubated for 2−3
min at room temperature, before the aqueous phase was
collected. Isopropanol was added to the precipitate and pellet
RNA using centrifuge (12 000g for 10 min in 4 °C). The pellet
was then washed with 75% ethanol, and the extracted RNA was
then dissolved in RNase-free water. The total extracted RNA in
each sample was determined by BioSpec-Nano spectropho-
tometer (Shimadzu, Columbia, MD). To synthesize cDNA, 0.5
μg of RNA was reverse-transcribed using an iScriptTM reverse
transcription supermix and a C1000 Touch thermocycler (Bio-
Rad, Hercules, CA), following the manufacturer’s guidelines. A
CFX96TM optical module (Bio-Rad, Hercules, CA) was used
for the RT-PCR analysis, where human β-actin was used as the
endogenous gene to normalize the mRNA level of targeted
proteins. Primers were designed using primer Blast software
available at The National Center for Biotechnology Information
website (http://www.ncbi.nlm.nih.gov/) and were synthesized
with the following sequences by IDT Technologies (Coralville,
Iowa): β-actin (forward: 5′-CCA CCC CAC TTC TCT CTA
AGG A-3′; reverse: 5′-AAT TTA CAC GAA AGC AAT GCT-
3′), KSP (forward: 5′-TCA CAA AAG CAA TGT GGA AAC
CTA-3′; reverse: 5′-TCT GTC CAA AGA TTCA TTA ACT
TGC A-3′), and JAK2 (forward: 5′-AAC TGC AGA TGC ACA
TCA TTA CCT-3′; reverse: 5′-TCG AAA TTG GGC CAT
GAC A-3′). Primers were validated to assure equal eﬃciency at
diﬀerent cDNA concentrations (−0.1 < slope < 0.1 for the
ΔCT vs cDNA dilution graph) and selectivity for the protein of
interest (by gel electrophoresis and determination of the length
of the resulting DNA). The mRNA levels were determined by
calculating ΔCT, ΔΔCT, and RQ using the endogenous gene
and “no treatment” group as reference points.
Statistical Analysis. The signiﬁcance of the diﬀerences
observed reported values (including siRNA uptake, mRNA
levels, and cell viability) were evaluated using Student’s t test (p
< 0.05). Standard deviations were calculated for all data and are
represented by the error bars in all ﬁgures. Pearson’s correlation
coeﬃcient was calculated where indicated, and its signiﬁcance
was determined by the t test, according to the following
equation
= −
−
t r
n
r
2
1 2
where r and n are the correlation coeﬃcient and the number of
samples, respectively. The calculated value of t was compared to
p values for each degree of freedom to determine the
signiﬁcance of the correlation.
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